Skye Bioscience, Inc.
No SEC Form 4 filings for $SKYE in the last 30 days.
See all $SKYE insider activity →Skye Bioscience (SKYE) and privately held Redx Pharma agreed to combine and form Fibrx Therapeutics, expected to trade on Nasdaq. The deal is slated to close in Q4 2026, led by Redx management. About $125M financing is planned. Lead asset RXC008 targets fibrotic Crohn’s, with Phase 2 topline expected H2 2028. SKYE trades at $0.54.
Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.
Skye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 projectsummit-transactiona.htm EX-2.1 Document ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brack
Over the past 7 days, alphai's AI scored 3 news stories mentioning SKYE (Skye Bioscience, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent SKYE coverage spans financial news, mergers & acquisitions and corporate actions.
Deal terms and financing imply a major corporate and pipeline reset for SKYE shareholders ahead of a Q4 2026 close.
Deal announcement and financing details create a near-term catalyst for SKYE around transaction closing mechanics and dilution expectations.
Deal-signing 8-K increases probability of a take-private or acquisition path, typically supporting near-term risk-on positioning but raising execution and approval risk.
Positive clinical trial update indicating safety and progress in drug development.
The approval to open a second cohort in Skye Bioscience's clinical study indicates ongoing progress and positive momentum, potentially supporting the stock's near-term price appreciation.
alphai scores every news story that mentions SKYE with an AI model for sentiment and relevance, and aggregates insider trades from Skye Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Skye Bioscience (SKYE) and privately held Redx Pharma agreed to combine and form Fibrx Therapeutics, expected to trade on Nasdaq. The deal is slated to close in Q4 2026, led by Redx management. About $125M financing is planned. Lead asset RXC008 targets fibrotic Crohn’s, with Phase 2 topline expected H2 2028. SKYE trades at $0.54.
3 min readSkye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.
4 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 projectsummit-transactiona.htm EX-2.1 Document ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brack
4 min readSkye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next-generation molecules to treat obesity and related conditions, with its lead candidate, nimacimab, undergoing Phase IIa clinical trials.
2 min readSkye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have reacted positively to the news, with shares trading near their 52-week high, and the company maintains a "GREAT" Financial Health score according to InvestingPro data.
3 min readThis page provides a comprehensive resource for Skye Bioscience (SKYE) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K material event forms. It details the company's regulatory disclosures, clinical programs, and financial condition. The platform offers AI-powered summaries, impact scoring, and sentiment analysis for these documents, facilitating deeper analysis for investors.
4 min readSkye Bioscience, Inc. is progressing with the development of nimacimab, aiming to optimize its dosing and exposure to maximize therapeutic potential, especially for targeting CB1 pathways. Early results from its CBeyond study, where nimacimab was combined with semaglutide, suggest that higher exposure levels might be necessary to engage peripheral CB1 targets more effectively. The company is evaluating nimacimab's clinical prospects and will report its Q4 and full-year 2025 financial results on March 10, 2026.
4 min readFaruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. (NASDAQ: SKYE) on behalf of investors who suffered losses between November 4, 2024, and October 3, 2025. This investigation follows the company's announcement on October 6, 2025, that its nimacimab monotherapy failed to meet its primary endpoint in a Phase 2a study, causing a significant drop in stock price. Investors are encouraged to contact the law firm to discuss their legal options or to seek a lead plaintiff role by the January 16, 2026 deadline.
3 min readNEW YORK, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. ( NASDAQ:SKYE ) between November 4, 2024 and October 3, 2025, both dates inclusive ( the "Class Period" ) , of the important January ...
3 min readLOS ANGELES, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ( "Skye" or "the Company" ) ( NASDAQ:SKYE ) for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated ...
2 min read
